Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

Highmark Health President and CEO David Holmberg discussed the uncertainties facing the insurance industry, including the ...

Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, a swallowable, procedureless intragastric balloon, in adults with obesity.

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

Tim Spector's health app Zoe analysed poop samples from over 21,000 people to find the best diet for the gut microbiome.

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

US households with users of GLP-1 drugs like Ozempic spend 6-9% less on groceries, with ultra-processed foods seeing the ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

GLP-1 weight-loss users shift their spending on food purchases both in and out of home. At grocery retail, they are spending more on foods that support GLP-1 balance, including vegetables, eggs and ...